Results 41 to 50 of about 44,321 (338)

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng   +3 more
doaj   +1 more source

Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices

Nature Communications, 2020
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl, Klaus Mayer, Felix Bormann, Harald Duerr, Eike Hoffmann, Bianca Nussbaum, Michael Tischler, Martina Wagner, Andreas Kuglstatter, Lea Leibrock, Can Buldun, Guy Georges, Ulrich Brinkmann   +12 more
doaj   +1 more source

AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma. [PDF]

J Manag Care Spec Pharm
Flavin B, Wolff D, Bobolts LR, Graff T, Hanna K, Haumschild R, Mok T, Shah B.   +7 more
europepmc   +3 more sources

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies [PDF]

, 2013
Background Since most glioblastomas express both wild-type EGFR and EGFRvIII as well as HER2/neu, they are excellent targets for activated T cells (ATC) armed with bispecific antibodies (BiAbs) that target EGFR and HER2.
A Formentini, A Pfosser, A Thakur, A Thakur, A Thakur, A Yamauchi, AB Heimberger, Archana Thakur, AT Ogden, BF Skinnider, G Jung, GA Niehans, Geoffrey R Barger, HE Lum, Ian M Zitron, J O’Connell, JF Mineo, JK Chan, JM Gall, K Ohshima, K Shiraki, KO Nam, L Davico Bonino, L Ren-Heidenreich, Lawrence G Lum, LG Lum, LM Weiner, M Al-Hajj, M Hahne, M Hishii, M Kawakami, M Sen, M Yankelevich, N Husain, Oxana Norkina, P Saas, PA Davol, RC Grabert, RO Dillman, Sandeep Mittal, SK Jacobs, SK Singh, T Hida, T Nishimura, T Nishimura, T Nitta, TA Dolecek, U Kapp, U Reusch, V Kolenko, X Yuan, Y Oshima   +51 more
core   +2 more sources

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

STAR Protocols, 2022
Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li, Alexander C. Partin, Liangjun Zhao, Irwin Chen, Mark L. Michaels, Zhulun Wang, Fernando Garces, Danyang Gong, Timothy P. Riley   +8 more
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia, Curnock, Adam, De Strooper, Bart, Dewilde, Maarten, Hassanzadeh-Ghassabeh, Gholamreza, Haustraete, Jurgen, Joyce, Peter, Lemmens, Robin, Little, Susan, Robberecht, Wim, Roucourt, Bart, Rue, Laura, Schoonaert, Lies, Timmers, Mieke, Van Damme, Philip, Van den Bosch, Ludo, Weber, Peter   +16 more
core   +2 more sources

Bispecific antibodies in cancer immunotherapy [PDF]

Current Opinion in Biotechnology, 2020
Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire   +2 more sources

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement [PDF]

, 2010
BACKGROUND: The complement system is not only a key component of innate immunity but also provides a first line of defense against invading pathogens, especially for viral pathogens.
Chuanfu Zhang, Fei Qiao, Hongbin Song, Huihui Chong, Leili Jia, Ligui Wang, Shaofu Qiu, Stephen Tomlinson, Weijing Liu, Yansong Sun, Yanwei Zhong, Yong Wang, Yuanyong Xu, Yusen Zhou, Yuxian He   +14 more
core   +2 more sources